Medical Research
The Hpv And Anal Cancer Foundation
NEW YORK, NY
Total revenue
$310K
Total expenses
$332K
Net assets
$1.0M
Grants received
$426K
21 grants
EIN
273217520
Tax year
2024
Mission
To empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, human papillomavirus (hpv).
Programs
2 programs
Patient: hpvacf provides robust resources, information and community initiatives to anal cancer patients and caregivers. Hpvacf educational and community forums bring patients, caregivers and providers together to empower each other and become informed. To address isolation in the community, hpvacf established the first formal anal cancer peer-peer support program that matches thrivers and caregivers with peers who have experienced anal cancer.
Research: hpvacf provides funding to accelerate new, effective drugs to treat hpv-related cancers, including anal cancer, and to build the scientific/medical infrastructure to create better treatment and prevention methods. This program has created the first anal neoplasia medical society, and funded ground-breaking research to find a cure for anal cancer and hpv-related cancers, especially in the field of immunotherapy.
Financials
FY 2024
Revenue
Expenses
People
4 listed
JUSTINE X ALMADA
EXECUTIVE DIRECTOR
$49K
40 hrs/wk
TRISTAN ALMADA
PRESIDENT
—
5 hrs/wk
CAMILLE ALMADA
VICE PRESIDENT & TREASURER
—
5 hrs/wk
CHRISTIAN LEVETT
DIRECTOR
—
1 hrs/wk
Grants received
Showing 21 of 21
Funded by
$426K from 12 funders · 21 grants · 2019–2024
$297K · 4 grants · 2019–2023
$36K · 5 grants · 2020–2024
$17K · 1 grant · 2024
$16K · 1 grant · 2019
$13K · 1 grant · 2022
$11K · 1 grant · 2019
$10K · 1 grant · 2019
$10K · 1 grant · 2021